Drug companies and hospitals are warring over a proposed administrative dispute resolution (ADR) program meant to settle long-running allegations over pricing and diversion of drugs in the 340B program. In this federally sponsored program, drug manufacturers sell medications at a discount to qualified hospitals and clinics, allowing them to generate revenue to expand services to generally low-income populations.
展开▼
